TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19892046

Group type: EXPERIMENTAL
Intervention: Core laboratory CK-MB values
Number of subjects: 913

Group type: COMPARATOR
Intervention: Site-reported CK-MB values
Number of subjects: 913

Group type: EXPERIMENTAL
Intervention: Patients with MI (core and site laboratory)
Number of subjects: 913

Group type: COMPARATOR
Intervention: Patients without MI (core or site laboratory)
Number of subjects: 913

Group type: EXPERIMENTAL
Intervention: Patients with MI (core laboratory but not site laboratory)
Number of subjects: 913
Study: 16672036

Group type: EXPERIMENTAL
Intervention: Dispersed housing in the community
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cluster centres
Number of subjects: 60
Study: 15243853

Group type: EXPERIMENTAL
Intervention: Active laser with dosage of 3 J/per painful point
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Active laser with dosage of 1.5 J/per painful point
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo laser treatment
Number of subjects: 60
Study: 11305843

Group type: EXPERIMENTAL
Intervention: Generic clozapine (mean daily dose of 630 mg)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Clozaril (mean daily dose of 610 mg)
Number of subjects: 45
Study: 9039090

Group type: EXPERIMENTAL
Intervention: Fenoldopam (0.1 to 0.2 microgram/kg per minute)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fenoldopam
Number of subjects: 24
Study: 7904847

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Triple therapy (CBS, tetracycline and metronidazole)
Number of subjects: 59

Group type: COMPARATOR
Intervention: H. pylori negative patients
Number of subjects: 59
Study: 3323596

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (mean 1.5 mg/kg/day) for 23 +/- 4 months
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide treatment
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (no cyclophosphamide)
Number of subjects: 26
Study: 29703585

Group type: EXPERIMENTAL
Intervention: Pilates exercises progression
Number of subjects: 139
Study: 27182016

Group type: EXPERIMENTAL
Intervention: K-MBSR program (8 sessions, once a week, 2.5 hours each)
Number of subjects: 52
Study: 24177203

Group type: EXPERIMENTAL
Intervention: Bosentan 125 mg bid for 16 weeks
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 22407134

Group type: EXPERIMENTAL
Intervention: Non-food odorant (jasmine)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Food odorant (green apple)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control odorant (water)
Number of subjects: 67
Study: 20691354

Group type: EXPERIMENTAL
Intervention: Twin-block appliance
Number of subjects: 64

Group type: COMPARATOR
Intervention: Dynamax appliance
Number of subjects: 64
Study: 18347003

Group type: EXPERIMENTAL
Intervention: Mentalization-based treatment by partial hospitalization
Number of subjects: 41
Study: 16238654

Group type: EXPERIMENTAL
Intervention: Diode laser-MTA pulpotomy
Number of subjects: 16

Group type: COMPARATOR
Intervention: Formocresol-ZOE pulpotomy
Number of subjects: 16
Study: 12405169

Group type: EXPERIMENTAL
Intervention: 7 days ceftriaxone therapy
Number of subjects: 73

Group type: COMPARATOR
Intervention: 10 days ceftriaxone therapy
Number of subjects: 73
Study: 10375084

Group type: EXPERIMENTAL
Intervention: Combined-modality therapy (CMT) consisting of radiation therapy (RT) and chemotherapy (CT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy (CT) alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiation therapy (RT) alone
Number of subjects: 0
Study: 7714757

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 12
Study: 2402811

Group type: EXPERIMENTAL
Intervention: Intravenous anaesthesia with propofol-fentanyl (Group I)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propofol-fentanyl anaesthesia with a supplement of nitrous oxide (Group II)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (I and II)
Number of subjects: 40
Study: 7358202

Group type: EXPERIMENTAL
Intervention: Conventional propranolol and bendrofluazide tablets given twice daily
Number of subjects: 14

Group type: COMPARATOR
Intervention: Combined capsule of propranolol and bendrofluazide given twice daily
Number of subjects: 14
Study: 31088143

Group type: EXPERIMENTAL
Intervention: Occupation-based multisensory stimulation and environmental enrichment intervention
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30
Study: 25658017

Group type: EXPERIMENTAL
Intervention: Subchronic sleep restriction (4 hours time in bed)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Normal sleep (8 hours time in bed)
Number of subjects: 14
Study: 23907451

Group type: EXPERIMENTAL
Intervention: Knee arthroplasty patients with complaints
Number of subjects: 200

Group type: COMPARATOR
Intervention: Symptom-free patients
Number of subjects: 200
Study: 21776546

Group type: EXPERIMENTAL
Intervention: Rehabilitation and early anterior cruciate ligament reconstruction (median of 44.5 days after the injury)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Rehabilitation and delayed anterior cruciate ligament reconstruction (408 days)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Rehabilitation alone
Number of subjects: 61

Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 61
Study: 18830236

Group type: EXPERIMENTAL
Intervention: Paroxetine dose escalation (30-50 mg per day as tolerable)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo dose escalation (paroxetine 20 mg per day + placebo)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Paroxetine dose escalation
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo dose escalation
Number of subjects: 107
Study: 16921503

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 154

Group type: COMPARATOR
Intervention: Control group (blood bank donors)
Number of subjects: 154
Study: 12846847

Group type: EXPERIMENTAL
Intervention: Sugar-substituted chewing gums
Number of subjects: 892

Group type: EXPERIMENTAL
Intervention: Fluoride toothpaste
Number of subjects: 892

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 892
Study: 10364988

Group type: EXPERIMENTAL
Intervention: Acute normovolaemic haemodilution (ANH)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Controlled hypotension
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 8909670

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 25

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 25
Study: 1905998

Group type: EXPERIMENTAL
Intervention: Gorging pattern (2 meals per day)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Nibbling pattern (7 meals per day)
Number of subjects: 13
Study: 6308063

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (3900 mg per day)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo (Ascorbic acid 1500 mg per day)
Number of subjects: 72
Study: 31088505

Group type: EXPERIMENTAL
Intervention: Midwifery continuity of care intervention
Number of subjects: 350

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 350
Study: 30526440

Group type: EXPERIMENTAL
Intervention: Autologous blood pleurodesis (ABP)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Talc pleurodesis
Number of subjects: 123
Study: 26859491

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure treatment (target SBP <140 mmHg)
Number of subjects: 1997

Group type: COMPARATOR
Intervention: Guideline-recommended blood pressure treatment (SBP <180 mmHg)
Number of subjects: 1997
Study: 25147350

Group type: EXPERIMENTAL
Intervention: Individually defined, targeted physical therapy program
Number of subjects: 10

Group type: COMPARATOR
Intervention: General physical therapy program
Number of subjects: 10
Study: 21861071

Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted right hemicolectomy (LARH)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Open right hemicolectomy (ORH)
Number of subjects: 145
Study: 19282241

Group type: EXPERIMENTAL
Intervention: Multimodal screening (MMS)
Number of subjects: 202638

Group type: EXPERIMENTAL
Intervention: Ultrasound screening (USS)
Number of subjects: 202638

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 202638
Study: 17517480

Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine/naloxone (4/1, 8/2, 16/4, 32mg/8mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Split doses of buprenorphine/naloxone (50% of the dose that precipitated withdrawal)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Full doses of buprenorphine/naloxone (100% of the dose that precipitated withdrawal)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intramuscular naloxone (0.2mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Oral methadone (100mg)
Number of subjects: 16
Study: 16387079

Group type: EXPERIMENTAL
Intervention: Lipo PGE1 therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no Lipo PGE1 therapy)
Number of subjects: 40
Study: 12218339

Group type: EXPERIMENTAL
Intervention: Vitamin E‐coated dialyzer
Number of subjects: 30

Group type: COMPARATOR
Intervention: Acrylonitrile dialyzer
Number of subjects: 30

Group type: COMPARATOR
Intervention: Polysulphone dialyzer
Number of subjects: 30
Study: 9469999

Group type: EXPERIMENTAL
Intervention: Dexamethasone (n = 55)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo (n = 54)
Number of subjects: 109
Study: 7619668

Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg daily
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg daily
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg daily
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Inhaled capsaicin
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group 1: Long-term enalapril treatment with no cough (n = 18)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group 2: Nifedipine (n = 17)
Number of subjects: 9
Study: 2404072

Group type: EXPERIMENTAL
Intervention: Immune DLE
Number of subjects: 14

Group type: COMPARATOR
Intervention: Nonimmune DLE
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Immune DLE (subsequent treatment)
Number of subjects: 14
Study: 31723956

Group type: EXPERIMENTAL
Intervention: Betacyanin-rich supplement of Opuntia stricta
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Betalain-rich supplement of red beetroot
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 29019951

Group type: EXPERIMENTAL
Intervention: High protein nutritional support (ONS)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group (no high protein nutritional support)
Number of subjects: 114
Study: 26057135

Group type: EXPERIMENTAL
Intervention: Tdap5 (2.5μg)
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Tdap1 (20μg)
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Both Tdap5 and Tdap1
Number of subjects: 705
Study: 23527804

Group type: EXPERIMENTAL
Intervention: SPDJCS (n=65)
Number of subjects: 165

Group type: COMPARATOR
Intervention: End-to-end/end-to-side invaginated anastomosis (Group A, n=52)
Number of subjects: 165

Group type: COMPARATOR
Intervention: End-to-side mucosal anastomosis (Group B, n=48)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Group A and Group B (n=100 combined)
Number of subjects: 165
Study: 21512490

Group type: EXPERIMENTAL
Intervention: Citalopran
Number of subjects: 0
Study: 19332722

Group type: EXPERIMENTAL
Intervention: ixabepilone plus capecitabine
Number of subjects: 0

Group type: COMPARATOR
Intervention: capecitabine alone
Number of subjects: 0
Study: 16844449

Group type: EXPERIMENTAL
Intervention: AESOP
Number of subjects: 20

Group type: COMPARATOR
Intervention: EndoAssist
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both robots
Number of subjects: 20
Study: 14599971

Group type: EXPERIMENTAL
Intervention: Tamoxifen + Octreotide (TAM+OCT)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Regular chemotherapeutic agents (5‐Fu and MMC)
Number of subjects: 39
Study: 10903022

Group type: EXPERIMENTAL
Intervention: Potassium canrenoate (PC) 400 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 20
Study: 8792792

Group type: EXPERIMENTAL
Intervention: Randomization in large studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preintervention and postintervention design
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unmeasured patient/error variance
Number of subjects: 0
Study: 1451519

Group type: EXPERIMENTAL
Intervention: Norethisterone 1 mg/ethinyl estradiol 35 micrograms (NET/EE)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Levonorgestrel 150 micrograms/ethinyl estradiol 30 micrograms (LNG/EE)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (IUD)
Number of subjects: 58
Study: 6328298

Group type: EXPERIMENTAL
Intervention: Acyclovir 200 mg five times daily
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Acyclovir 200 mg twice daily
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study: 30209575

Group type: EXPERIMENTAL
Intervention: Single crown group (190 crowns)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Retainer crown group (276 retainer crowns)
Number of subjects: 233
Study: 29424490

Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR) 25% for 2 years
Number of subjects: 218

Group type: COMPARATOR
Intervention: Ad libitum control (AL)
Number of subjects: 218
Study: 27824606

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 24491079

Group type: EXPERIMENTAL
Intervention: Self-affirming implementation intention
Number of subjects: 67

Group type: COMPARATOR
Intervention: Distractor task
Number of subjects: 67
Study: 22139613

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab injection and panretinal photocoagulation (PRP)
Number of subjects: 19

Group type: COMPARATOR
Intervention: PRP alone
Number of subjects: 19
Study: 20068257

Group type: EXPERIMENTAL
Intervention: Vitamin D with calcium
Number of subjects: 68517

Group type: EXPERIMENTAL
Intervention: Vitamin D alone (10 microg or 20 microg)
Number of subjects: 68517
Study: 17414400

Group type: EXPERIMENTAL
Intervention: New Zealand candidate vaccine (25 microg/dose) administered at 0, 6, and 12 weeks
Number of subjects: 332

Group type: COMPARATOR
Intervention: Norwegian parent vaccine (25 microg/dose) administered at 0, 6, and 12 weeks
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 332
Study: 15826227

Group type: EXPERIMENTAL
Intervention: Objects moving at different speeds (manipulated speed of objects)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scene undergoing translation, zoom, rotation, or combinations of these motions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interference with observers' ability to see a coherent scene (moving objects at different speeds and distorting perception of 3-D space)
Number of subjects: 0
Study: 11953964

Group type: EXPERIMENTAL
Intervention: Combination of DMARDs (sulfasalazine, methotrexate, hydroxychloroquine, and prednisolone)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Single DMARD with or without prednisolone
Number of subjects: 195
Study: 11596586

Group type: EXPERIMENTAL
Intervention: Lung-volume-reduction surgery
Number of subjects: 69

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 69
Study: 9172212

Group type: EXPERIMENTAL
Intervention: Blocked presentation of words
Number of subjects: 60

Group type: COMPARATOR
Intervention: Random presentation of words
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Blocked presentation of pictures
Number of subjects: 60

Group type: COMPARATOR
Intervention: Random presentation of pictures
Number of subjects: 60
Study: 8170449

Group type: EXPERIMENTAL
Intervention: Oral and dietary hygiene instructions (Group 1: 492 children)
Number of subjects: 1475

Group type: EXPERIMENTAL
Intervention: Oral and dietary hygiene instructions + fluoro-prophylactic treatment (Group 2: 501 children)
Number of subjects: 1475

Group type: COMPARATOR
Intervention: No instructions or treatment (Control Group 3: 482 children)
Number of subjects: 1475
Study: 2832935

Group type: EXPERIMENTAL
Intervention: Thiazide + unprocessed bran (50 mg b.i.d. from May to September)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Unprocessed bran (40 g daily)
Number of subjects: 73
Study: 29152828

Group type: EXPERIMENTAL
Intervention: EBR/GZR + RBV
Number of subjects: 70

Group type: COMPARATOR
Intervention: GZR + RBV
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: EBR/GZR
Number of subjects: 70
Study: 25628299

Group type: EXPERIMENTAL
Intervention: NYU Caregiver Intervention for Adult Children (NYUCI‐AC)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Contact control group
Number of subjects: 107
Study: 25912760

Group type: EXPERIMENTAL
Intervention: Usual gait training plus kinematic feedback
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual gait training
Number of subjects: 24
Study: 23097006

Group type: EXPERIMENTAL
Intervention: Primary 2:1 bipolar/unipolar mode (group B)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Primary 4:1 bipolar/unipolar mode (group A)
Number of subjects: 44
Study: 20803854

Group type: EXPERIMENTAL
Intervention: Crystalloid preload anaesthesia (20 mL/kg lactated Ringer's solution)
Number of subjects: 62

Group type: COMPARATOR
Intervention: No preload anaesthesia
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Crystalloid preload anaesthesia
Number of subjects: 62
Study: 19808296

Group type: EXPERIMENTAL
Intervention: Sildenafil (selective pulmonary vasodilator)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 16772327

Group type: EXPERIMENTAL
Intervention: L-arginine (8.3 g/day)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 14526887

Group type: EXPERIMENTAL
Intervention: Family Focused Grief Therapy (FFGT)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Family Relationships Index (FRI)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Beck Depression Inventory (BDI)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Brief Symptom Inventory (BSI)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Social Adjustment Scale (SAS)
Number of subjects: 81
Study: 11071165

Group type: EXPERIMENTAL
Intervention: Small‐incision cholecystectomy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy
Number of subjects: 200
Study: 8791240

Group type: EXPERIMENTAL
Intervention: 6 mg sumatriptan s.c.
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 1612732

Group type: EXPERIMENTAL
Intervention: Spherule vaccine
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Coccidioidomycosis patients
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: HIV-infected patients
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Patients without evident coccidioidomycosis
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Patients with histoplasmosis
Number of subjects: 37
Study: 31629546

Group type: EXPERIMENTAL
Intervention: Smokers according to NLST criteria
Number of subjects: 1601

Group type: EXPERIMENTAL
Intervention: Smokers according to NELSON criteria
Number of subjects: 1601

Group type: EXPERIMENTAL
Intervention: Former smokers according to NLST criteria
Number of subjects: 1601

Group type: EXPERIMENTAL
Intervention: Former smokers according to NELSON criteria
Number of subjects: 1601

Group type: EXPERIMENTAL
Intervention: Nicotine dependence measured with the brief Fagerström test
Number of subjects: 1601
Study: 29383698

Group type: EXPERIMENTAL
Intervention: Infusion method TOV
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard auto-fill method TOV
Number of subjects: 40
Study: 26467209

Group type: EXPERIMENTAL
Intervention: Fexofenadine
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: EXP3174
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Hydroxyitraconazole
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: All drugs
Number of subjects: 464
Study: 23331874

Group type: EXPERIMENTAL
Intervention: ipulse personal home-use intense pulsed light (IPL) device, treated once weekly for four consecutive weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control site (contralateral axilla)
Number of subjects: 10
Study: 22802542

Group type: EXPERIMENTAL
Intervention: Severe somatic dysfunction in the lumbar region
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Severe somatic dysfunction in the sacrum/pelvis region
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Increasing number of key lesions
Number of subjects: 455
Study: 20847105

Group type: EXPERIMENTAL
Intervention: Folic acid 100 μg/day
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Folic acid 400 μg/day
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Folic acid 1,000 μg/day
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Folic acid 2,000 μg/day
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Folic acid supplementation in participants with low serum folate (<4.5 ng/mL)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study: 18665698

Group type: EXPERIMENTAL
Intervention: Panic Control Treatment (PCT)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Psychoeducational Supportive Treatment (PE-SUP)
Number of subjects: 35
Study: 16879670

Group type: EXPERIMENTAL
Intervention: Suburethral sling
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no sling)
Number of subjects: 49
Study: 12641643

Group type: EXPERIMENTAL
Intervention: Proprioceptive training (PT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Strength training (ST)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both PT and ST
Number of subjects: 10